BioSpace News Archive

BiondVax Pharmaceuticals Ltd., which focuses on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced the signing of a term sheet that includes binding financial terms of contemplated definitive agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.

ImpriMed, Inc., a leading functional precision medicine company in veterinary oncology that provides a personalized drug response profiling service announced the additional diagnostic services to their most advanced functional precision medicine service for canine hematopoietic cancers.

NextCure, Inc. (Nasdaq: NXTC), today announced the appointments of Elizabeth Jaffee, M.D., Ursula Matulonis, M.D., and Weiping Zou, M.D., Ph.D., to its Scientific Advisory Board (SAB). Ethan Shevach, M.D., will retire from the SAB. Drs. Lieping Chen, M.D., Ph.D., Mario Sznol, M.D., and Stephen Miller, Ph.D., will continue to serve on the SAB.

InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV) will release its 2022 fiscal first quarter financial results on Tuesday, November 9, 2021, after market close.

X4 Pharmaceuticals, Inc. announced the appointment of Françoise de Craecker to the company’s Board of Directors and the recent hiring of Karolyn Park to the newly created role of Vice President, U.S. Commercial, significantly strengthening the company’s depth and breadth of commercial leadership experience.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has enrolled the first patient in its Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD).

Applied Genetic Technologies today announced Sue Washer, President and Chief Executive Officer of AGTC, will present at the Dry AMD Therapeutic Development Summit being held virtually October 19 – 21, 2021.

PharmAbcine Inc. announced today that the patent for PMC-309, one of the Company’s first immuno-oncology assets, has been granted by IP Australia, the Australian government agency

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the launch of FeraMAX ® Pd Powder 15 by its subsidiary, BioSyent Pharma Inc., in Canada.

Evert Kroon , Ph.D., Vice President of Translation Research at ViaCyte, Inc. will participate in the International Pancreas & Islet Transplantation Association (IPITA) Virtual Congress’ session, " Islet Organoids From Pluripotent and Adult Stem Cells " on Friday, October 22, 2021 from 8:05-9:05 a.m. ET.